---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018477"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:36:01.503030+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q1 2023 net loss $27.7M; cash runway unchanged into Q4 2024

## Summary
- Net loss $27.7M ($0.58 loss per share) vs $29.5M ($0.63) in Q1 2022.
- Cash, cash equivalents & marketable securities $172.3M; funding operations into Q4 2024.
- R&D expenses decreased to $21.8M from $22.8M YoY.
- PRT2527 CDK9 inhibitor solid tumor dose escalation complete; RP2D in hematological malignancies expected 2H 2023.
- Phase 1 dose escalation of PRT3789 (SMARCA2 degrader) ongoing; oral candidate nomination expected early 2024.

## SEC filing metadata
- accession: 0000950170-23-018477
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017023018477/0000950170-23-018477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017023018477/prld-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018477
- JSON: https://secwatch.observer/filing/0000950170-23-018477.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018477.txt

## Key facts
- Earnings Releases
  Prelude Therapeutics Inc reported first quarter ended March 31, 2023 results: net income $27.7 million, EPS $0.58 per share.
  - Period: first quarter ended March 31, 2023
  - Net income: $27.7 million
  - EPS: $0.58 per share
  - Result: reported results
  source text: Net Loss: For the three months ended March 31, 2023, net loss was $27.7 million, or $0.58 per share compared to $29.5 million, or $0.63 per share, for the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017023018477/0000950170-23-018477-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.